Overview of the Decade of Vaccines Collaboration including background, structure and vision for creation of the Global Vaccines Action Plan.
www.dovcollaboration.org
2. Contents Setting the Stage โ A Decade of Vaccines Why we should prioritise vaccines & immunization โ progress, proof and momentum Decade of Vaccines vision Why act now? Vaccine life cycle What is the Decade of Vaccines Collaboration? Decade of Vaccines Collaboration structure Working Groups overview and cross-cutting issues Further information
3. Setting the Stage โ A โDecade of Vaccinesโ In January 2010, Bill & Melinda Gates called for the next ten years to be the โDecade of Vaccines.โ The announcement included a commitment from their foundation of US$10 billion over the next 10 years to realize a vision embraced by the global community: โto help research, develop and deliver vaccines for the worldโs poorest countriesโ Millions of deaths could be averted by significantly scaling up the delivery of life-saving vaccines in developing countries to 90% coverage and rapidly introducing new vaccines
4. Vaccines & Immunization โ Real progress made in recent years Last 20 years has seen a huge rise in the number of new vaccines โ especially against the leading causes of child deaths: pneumonia & diarrhea WHO data show global vaccination rates have reached all-time highs โ rebounding from years of decline in the 1990s 106 million children were vaccinated in 2008 and global immunization rates are at their highest level ever BUTโฆ despite this progress, nearly 23.5 million children are still not fully immunized every year
5. Vaccines prove that smart aid works Vaccines are the most cost effective way to prevent disease and give children a healthy start to life Vaccines are proven โ 20 years ago, global health leaders resolved to wipe polio off the planet and today weโre 99 percent of the way there Major vaccine manufacturers have announced significant price cuts for their vaccines Reducing prices of available vaccines and creating opportunities for better, cheaper vaccines will ensure that current and future funding can save even more lives
6. Momentum is building for vaccines & immunization All 193 Member States approved the need for a global vaccine action plan at the 64th World Health Assembly, May 2011 In June 2011, donors committed $4.3 billion in funding to the GAVI Alliance โ to help immunize more than 250 million peoplein developing countries by 2015
7. โWe envision a world where children, families, and communities enjoy life protected from the threat of disease. The purpose of the Decade of Vaccines is to extend the full benefits of immunization to all people, regardless of where they liveโ Decade of Vaccines vision
8. This is a unique moment in time that we must seize, turning the moment into a movement: Why now? A unique opportunity New and existing vaccines are ready for country immunization programs: pneumonia, diarrheal disease, meningitis A, cervical cancer, polio and measles Candidate vaccines are in the pipeline: malaria, HIV, tuberculosis Demand for vaccines is increasing, and national governments are prioritizing vaccines in their health strategies
9. Vaccine Life Cycle from Optimize: Immunization Systems and Technologies for Tomorrow, PATH and the World Health Organization
10. Decade of Vaccines (DoV) Collaboration The aim of the DoV Collaboration is to enhance coordination across the global community by creating a global vaccine action plan: The DoV Collaboration represents the first step in the Decade of Vaccines It is a time-limited global effort, led by a Steering Committee of global health experts, to outline how the international community can best use vaccines to save lives The consultation process was launched at the World Health Assembly (WHA) in 2011 and the plan will be presented in 2012
11. Our Structure Leadership Council Steering Committee Co-Chairs: Prof. Pedro Alonso Dr Christopher Elias Secretariat AtโLarge Steering Committee Members Public & Political Support Co-Chairs Delivery Co-Chairs R&D Co-Chairs Global Access Co-Chairs Public & Political Support Working Group Delivery Working Group R&D Working Group Global Access Working Group
12. Leadership Council Mr. Anthony Lake Executive Director UNICEF Dr. Margaret Chan Director General World Health Organization Dr. Rajeev VenkayyaDirector, Global Health Vaccine DeliveryBill & Melinda Gates Foundation Dr. Anthony Fauci Director National Institute of Allergy and Infectious Diseases Ms. Joy Phumaphi Executive Secretary African Leaders Malaria Alliance
13. Steering Committee Prof. Pedro Alonso(Co-chair) Dr. Christopher Elias (Co-chair) Ms. Helen Evans Dr. Lola Dare Dr. Zulfiqar Bhutta Dr. Ciro de Quadros Dr. Lee Hall Dr. Jos Vandelaer Dr. Orin Levine Dr. Jean Marie Okwo-Bele Dr. T. Jacob John Dr. Nicole Bates Dr. Peter Singer Dr. Anne Schuchat Prof. David Salisbury Ms. Sandy Wrobel Dr. Seth Berkley Dr. Lucky Slamet Dr. Gina Tambini
14. Charter: Prevent, eliminate or eradicate diseases by means of achieving high and equitable coverage with effective and safe immunization along with other essential healthcare interventions Scope: Build upon the current Global Immunization Vision and Strategy Help ensure country consultation and engagement Develop recommendations for improving immunization systems as a platform to prevent mortality and morbidity Create estimates of costs and financing for delivery Co-Chairs:Dr. Jean Marie Okwo-Bele (Director, WHO Department of Immunization, Vaccines and Biologicals) and Dr. Jos Vandelaer (Chief, Immunization, Programme Division, UNICEF) Working Group: Delivery
15. Working Group: Global Access Charter:Develop an action plan that helps to ensure global access to an adequate supply of high quality affordable vaccines with formulations and presentations that meet the needs of all countries Scope: Efficient and effective supply procurement strategy Affordable pricing strategy Comprehensive financing strategy Approaches to meet projected financing needs Approaches to get greater return on available financing Improved demand forecasting methods and tools Co-Chairs: Dr. Orin Levine (Executive Director, International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health) and Ms. Sandy Wrobel (CEO and Managing Director, Applied Strategies)
16. Working Group: Public & Political Support Charter:Strengthen public and political support for vaccines Scope: To facilitate networking of the academic and advocacy communities around a shared agenda To synthesize key foci related to the existing evidence base, identifying gaps and essential policy research questions To advise other DoV Collaboration Working Groups by applying an advocacy filter to technical products Co-Chairs: Dr. Nicole Bates (Senior Program Officer, Global Health Policy and Advocacy, Bill & Melinda Gates Foundation) and Dr. Peter Singer (Director, McLaughlin Rotman Centre for Global Health, University of Toronto)
17. Working Group: Research & Development Charter: Maintain a strong pipeline of research and developmentto ensure that vaccines will improve the lives of children beyond this decade Scope: Rationalize the balance between priority vaccines based on objective criteria and feasibility for product development Identifying a process for translating Working Group outputs / recommendations into funded research programmes / projects Costing of outputs / recommendations Co-Chairs: Dr. Seth Berkley (CEO, GAVI Alliance) and Prof. David Salisbury (Director of Immunization, UK Department of Health)
19. Consultation: Seeking input It will be an entirely transparent process, both in fact and appearance As a first step, the DoV Collaboration will make information available on how to participate and how to input โ either in person or online Consultation to target ALL the stakeholders and themes of the DoV Collaboration Regional consultations to take place in Africa, Americas, Asia, Europe Input solicited around four working group themes and cross-cutting topics The output will be a global vaccine action plan delivered in 2012
20. Global Vaccine Action Plan The global vaccine action plan will incorporate input from the consultation process and build on current work and include recommendations on: Expanding the delivery and use of new and under-utilized vaccines Forging mutually beneficial alliances with the private sector to develop and deliver vaccines Cultivating a robust scientific enterprise to discover and develop new vaccines Empowering communities to advocate for policies that will improve the health of their children and families
21. Critical Success Factors of the DoV Collaboration To foster active participation of the international vaccine community to define and execute a comprehensive effort to improve and save lives through vaccines To deliver a global vaccine action plan that turns the Decade of Vaccines vision into a reality To ensure continued engagement of groups and individuals, who are all committed to the planโs implementation
22. Access to safe and effective vaccines is human right not currently enjoyed by everyone, particularly those in low- and middle-income countries. In this decade, we can significantly advance global health and save millions of lives. โThe Decade of Vaccines needs unprecedented action. Itโs absolutely crucial that both governments and the private sector step up efforts to provide life-saving vaccines to children who need them mostโ Margaret ChanWHO Director-General
23. For further information Website: www.dovcollaboration.org Email: info@dovcollaboration.org @DofVC
Editor's Notes
- According to recent analysis using a model developed by Johns Hopkins University School of Public Health,the deaths of some 5.6 million children under 5 could be prevented from 2011-2020 by significantly scaling up the delivery of life-saving vaccines in developing countries to 90 percent coverage, and rapidly introducing new vaccines.
- The pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RV) protect against the leading causes of pneumonia and diarrhoea, respectively. By themselves, these vaccines could save about 1 million childrenโs lives every year- There used to be a lag of 15-20 years before a child in a poor country would get the same vaccines that a child in a rich country did โ now we have the chance to deliver new vaccines to all children.
- For a few dollars per child, vaccines can prevent disease for a lifetime:Polio vaccines are available for 13 cents per dose, measles for 23 cents per dose and, as of December 2010, meningitis vaccines are available in Africa for less than 50 cents per dose.
- In this decade, we can revolutionize global health and save millions of lives-New vaccines are ready now for countriesโ immunization programsโฆ New and existing vaccines against pneumonia, diarrheal disease, Meningitis A, cervical cancer, polio and measles are available right now, and are being made available in Africa while they are currently available in many other parts of the world โ it used to take 30 years before a vaccine available to American children would be given to African children- Effective candidate vaccines are in the pipelineโฆ A malaria vaccine is in the final stages of clinical trials and could be available as early as 2014 and progress continues in the pursuit of new vaccines for diseases like HIV and tuberculosis National governments are prioritizing vaccines in their health strategiesโฆ With the growing community demand for vaccines, governments have dedicated more resources to immunizing their citizens - helping to increase immunization rates to 82% from 74% in 2000[WHO Global immunization strategy and vision, Report by the Secretariat, 25 Nov 2010]
The DoV Collaboration acts as a catalyst and as a convener:As a catalyst, the DoV Collaboration enhances coordination across the international vaccine community to transform its approach to reaching vulnerable populationsAs a convener, the DoV Collaboration is bringing together diverse stakeholders to develop an evidence-based, country-led global vaccine action plan The Decade of Vaccines Collaboration itself is a time-limited consultation processThe ultimate success of this plan depends on the continued engagement of groups and individuals, academics and advocates, donors and recipients, who are all committed to its implementation- Achieving the goals of the DOV Collaboration will require increased funding and active participation from every sector to help define and execute a comprehensive effort to improve and save lives through vaccines
The structure of the Decade of Vaccines Collaboration includes a Leadership Council to provide oversight for the planning effort, a Steering Committee that holds the primary responsibility for developing the action plan, an International Advisory Committee to assist the Leadership Council in evaluating the action plan, and a Secretariat for administrative supportThe Decade of Vaccines Collaboration is led by a 19-member Steering Committee. The co-chairs are Prof. Pedro Alonso, Director of the Institute for Global Health of Barcelona, and Dr. Christopher Elias, President and CEO of PATH, both serving in an individual, not institutional, capacity- The World Health Organization, UNICEF, the National Institute of Allergy and Infectious Diseases, the African Leaders Malaria Alliance, and the Bill & Melinda Gates Foundation are represented on the Leadership Council
The Leadership Council launched the Decade of Vaccines Collaboration and continues to provide oversight to the planning process. It is comprised of leading figures from the organizations overseeing the Decade of Vaccines Collaboration vision:Margaret Chan โ World Health Organization Anthony Lake โ UNICEFAnthony Fauci โ National Institute of Allergy and Infectious DiseaseDr. Rajeev Venkayyaโ Bill & Melinda Gates Foundation Joy Phumaphi โ African Leaders Malaria Alliance They believe that this represents a unique moment in time and that now is the time to challenge the global community to deliver the vision of a world where children, families, and communities enjoy life protected from the threat of disease.
The Steering Committee is the driving force behind the development of the global vaccine action plan. The Steering Committee guides the work and consultation process of the four working groups (Public & Political Support, Delivery, R&D, and Global Access) and identifies cross-cutting issues to be addressed as part of the development of the plan.ย
Co-Chairs: Dr. Jean Marie Okwo-Bele (Director, WHO Department of Immunization, Vaccines and Biologicals) and Dr. Jos Vandelaer (Chief, Immunization, Programme Division, UNICEF)
Co-Chairs: Dr. Orin Levine (Executive Director, International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health) and Ms. Sandy Wrobel (CEO and Managing Director, Applied Strategies)
Co-Chairs: Dr. Nicole Bates (Senior Program Officer, Global Health Policy and Advocacy, Bill & Melinda Gates Foundation) and Dr. Peter Singer (Director, McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto Director)
Co-Chairs: Dr. Seth Berkley (CEO, GAVI Alliance) and Prof. David Salisbury (Director of Immunization, UK Department of Health)
The Decade of Vaccines Collaboration has identified a number of topics which cut across the mandates of the four Working Groups. This chart outlines the preliminary cross-cutting issues that have been identified and the groups that will work together to develop relevant recommendations for the global vaccine action plan: Community demand and country engagement cross both the mandates of PPS and Delivery Working Groups Regulatory issues, operational/transformational research, and policies/technology for delivery were identified as cross-cutting issues for R&D and Delivery Working Groups Supply, procurement, demand forecasting and costing are issues that cross both the Delivery and Global Access Working Groups Health systems also need to be considered as an additional cross-cutting issue. The Decade of Vaccines Collaboration understands the importance of involving and giving voice to recipient communities and individuals in this process in order to guarantee success
Many diverse groups will contribute to the plan โ recipient countries, civil society, national governments, donors, multilateral and bilateral organizations, industry, philanthropy, and academiaSolicit inputs, views, evidence, and information from a diverse group of stakeholders Together, they will identify critical gaps in policy, funding, and other areas that must be addressed to realize the life-saving potential of vaccines From Autumn 2011, the Decade of Vaccines Collaboration will undertake a consultation process, engaging a wide range of stakeholders on a number of policy, economic, health, delivery, and epidemiological issues and challenges related to how best to use vaccines- To ensure a diversity of views, individuals and organizations will be invited to participate in a series of in-person and online consultations to provide Working Groups with evidence and guidance in priority areas
- The plan will outline how best to get life-saving vaccines to the children who need them most, maintain a strong pipeline of new vaccines, and strengthen support for these efforts. Recommendations will address all aspects of the vaccination continuum, including discovery, development, and delivery.
- The community is defined as: Recipient countries, multilateral & bilateral organizations, civil society, donor nations, the private sector, academic institutions, and philanthropic organizations